ZA200805346B - A process for concentration of a polypeptide - Google Patents

A process for concentration of a polypeptide

Info

Publication number
ZA200805346B
ZA200805346B ZA2008/05346A ZA200805346A ZA200805346B ZA 200805346 B ZA200805346 B ZA 200805346B ZA 2008/05346 A ZA2008/05346 A ZA 2008/05346A ZA 200805346 A ZA200805346 A ZA 200805346A ZA 200805346 B ZA200805346 B ZA 200805346B
Authority
ZA
South Africa
Prior art keywords
polypeptide
concentration
Prior art date
Application number
ZA2008/05346A
Other languages
English (en)
Inventor
Stefan Nilsson
Original Assignee
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex As filed Critical Zymenex As
Publication of ZA200805346B publication Critical patent/ZA200805346B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2008/05346A 2006-04-04 2008-06-19 A process for concentration of a polypeptide ZA200805346B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
ZA200805346B true ZA200805346B (en) 2018-11-28

Family

ID=38472949

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2008/05346A ZA200805346B (en) 2006-04-04 2008-06-19 A process for concentration of a polypeptide
ZA2008/09540A ZA200809540B (en) 2006-04-04 2008-11-07 A process for concentration of a polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2008/09540A ZA200809540B (en) 2006-04-04 2008-11-07 A process for concentration of a polypeptide

Country Status (20)

Country Link
US (6) US20090246187A1 (enExample)
EP (4) EP2004672B1 (enExample)
JP (6) JP2009532394A (enExample)
KR (3) KR20150103339A (enExample)
CN (1) CN105233276A (enExample)
AU (2) AU2007234195B2 (enExample)
BR (1) BRPI0709737A2 (enExample)
CA (3) CA2644642C (enExample)
DK (1) DK2628746T3 (enExample)
ES (3) ES2713488T3 (enExample)
HU (1) HUE042402T2 (enExample)
IL (4) IL194267A (enExample)
MX (1) MX2008012748A (enExample)
NO (3) NO347673B1 (enExample)
NZ (7) NZ607595A (enExample)
PL (3) PL2631242T3 (enExample)
PT (1) PT2628746T (enExample)
SI (1) SI2628746T1 (enExample)
WO (1) WO2007112757A2 (enExample)
ZA (2) ZA200805346B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
PL2631242T3 (pl) * 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu
EA022220B1 (ru) * 2010-02-24 2015-11-30 Сюменекс А/С Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы
DK2588130T3 (en) * 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
NZ605873A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
NZ707753A (en) * 2012-11-13 2019-07-26 Chiesi Farm Spa Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
EP2932274B1 (en) * 2012-12-11 2020-01-15 Centogene AG Method for the diagnosis of metachromatic leukodystrophy
CN119979504A (zh) 2013-01-09 2025-05-13 武田药品工业株式会社 含用于纯化芳基硫酸酯酶a的方法
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
EP1049487B1 (en) 1998-01-27 2002-05-22 Hemebiotech A/S Treatment of acute intermittent porphyria (aip) and other porphyric diseases
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
PL196770B1 (pl) * 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ／エス ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
AU2002317701A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003002731A1 (en) * 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
PL2631242T3 (pl) * 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu

Also Published As

Publication number Publication date
CA2644642C (en) 2016-01-26
BRPI0709737A2 (pt) 2011-07-26
JP2013236633A (ja) 2013-11-28
IL194267A (en) 2015-10-29
PL2628746T3 (pl) 2019-07-31
CA2632528C (en) 2022-07-12
WO2007112757A3 (en) 2008-02-28
NO347673B1 (no) 2024-02-19
JP2014058521A (ja) 2014-04-03
US20180289777A1 (en) 2018-10-11
CA2632528A1 (en) 2007-10-11
JP2009273469A (ja) 2009-11-26
KR20150103339A (ko) 2015-09-09
NO20211305A1 (no) 2008-10-31
NO20082510L (no) 2008-10-31
US20090246187A1 (en) 2009-10-01
CA2882501A1 (en) 2007-10-11
NZ597548A (en) 2013-08-30
JP2016104000A (ja) 2016-06-09
IL241654A0 (en) 2015-11-30
NZ582045A (en) 2011-07-29
NZ623123A (en) 2015-04-24
KR20090018894A (ko) 2009-02-24
AU2007234195B2 (en) 2013-02-07
KR101504969B1 (ko) 2015-03-24
KR20140057678A (ko) 2014-05-13
AU2007234195A1 (en) 2007-10-11
ES2713488T3 (es) 2019-05-22
NZ571610A (en) 2011-07-29
EP2631242A3 (en) 2013-10-02
EP2004672B1 (en) 2015-08-19
NO346368B1 (no) 2022-06-27
MX2008012748A (es) 2009-01-07
NZ588903A (en) 2012-08-31
US20160193304A1 (en) 2016-07-07
EP2100898A1 (en) 2009-09-16
CN105233276A (zh) 2016-01-13
US20140314735A1 (en) 2014-10-23
NZ568728A (en) 2011-09-30
EP2628746A3 (en) 2014-03-19
JP5384232B2 (ja) 2014-01-08
US9713634B2 (en) 2017-07-25
IL211905A0 (en) 2011-05-31
PL2631242T3 (pl) 2023-03-20
ES2744499T3 (es) 2020-02-25
CA2644642A1 (en) 2007-10-11
EP2628746A2 (en) 2013-08-21
US20170202927A1 (en) 2017-07-20
IL235982A0 (en) 2015-01-29
EP2628746B1 (en) 2019-01-09
IL241654B (en) 2019-02-28
JP2014051503A (ja) 2014-03-20
ZA200809540B (en) 2019-09-25
EP2631242B1 (en) 2022-08-03
HUE042402T2 (hu) 2019-06-28
WO2007112757A2 (en) 2007-10-11
ES2928096T3 (es) 2022-11-15
PT2628746T (pt) 2019-04-23
US8809055B2 (en) 2014-08-19
AU2008229659A1 (en) 2008-10-23
AU2008229659B2 (en) 2013-01-31
NZ607595A (en) 2014-10-31
EP2004672A2 (en) 2008-12-24
DK2628746T3 (en) 2019-04-01
PL2100898T3 (pl) 2019-11-29
JP5878152B2 (ja) 2016-03-08
US20120076767A1 (en) 2012-03-29
CA2882501C (en) 2021-09-07
SI2628746T1 (sl) 2019-04-30
JP2009532394A (ja) 2009-09-10
EP2100898B1 (en) 2019-06-19
EP2631242A2 (en) 2013-08-28
NO20084776L (no) 2008-10-31
IL194267A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
IL241654A0 (en) A process for concentrating a polypeptide
IL207429A0 (en) A method of purifying a peptide
PL2423315T3 (pl) Sposób osiągania lepszej ekspresji polipeptydu
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
IL197765A0 (en) Methods for purification of polypeptide conjugates
ZA200900836B (en) Process for the purification of FC-fusion proteins
GB0619941D0 (en) Chemical process
ZA200704159B (en) Method for analysis of pellet-cladding interaction
PT2079843T (pt) Processo para a produção de biogás
IL197979A0 (en) Method for peptide synthesis
EP2088136A4 (en) PROCESS FOR PRODUCING HYDROXYADAMANTANE-AMINE
GB0619942D0 (en) Chemical process
EP2045324A4 (en) METHODS FOR PRODUCING THE N36 BINDING PEPTIDE
EP2006302A4 (en) PROTEIN COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
GB2471802B (en) Chemical process
EP1968934A4 (en) METHOD FOR OBTAINING PURE OSELTAMIVIR
HK1120274A (en) A process for concentration of a polypeptide
GB2440637B (en) Method of facilitating analysis of a peptide
GB2471803B (en) Chemical process
IL181944A0 (en) A process for the concentration of hcl
GB0610386D0 (en) Chemical process
GB0618832D0 (en) Chemical process
GB0805124D0 (en) Process for modifying proteins
IL193470A0 (en) Process for preparing of 2-alkyl-3-aryl-prop-2- ene-1-ols
GB0624029D0 (en) Process for capture of carbon